Compare DexCom, Inc. (DXCM) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs LyondellBasell Industries NV — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while LyondellBasell Industries NV trades at $60.34 (market cap $19.49B). The key difference: DexCom, Inc. is the larger of the two by market cap, and LyondellBasell Industries NV pays a 4.57% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and LyondellBasell Industries NV for 87 Days on average.
| DXCM | LYB | |
|---|---|---|
Market Cap | $31.86B | $19.49B |
Volume | 3,607,070 | 6,033,396 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $82.38 |
52-Week Low | $54.84 | $42.28 |
Typical Hold Time | 62 Days | 87 Days |
Enterprise Value | $31.32B | $31.08B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
LyondellBasell (LYB) trades at $58.49, down 0.75% on the day, amid a bearish technical signal and mixed fundamentals. The company reported a net loss of $745 million in 2025, with negative profit margins, though recent quarterly EPS beats and a consensus price target of $69.38 suggest recovery potential. Cash flow remains positive, and a $0.69 dividend is scheduled for payment on August 31, 2026, but declining revenue and high debt levels pose challenges.
The outlook for LYB hinges on earnings recovery and cost management, with analyst sentiment evenly split between buy and hold. Key risks include volatile chemical markets and high leverage, while institutional activity shows mixed positioning. The stock offers value based on P/S and P/B ratios but requires monitoring of profitability trends and debt sustainability for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
